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INTRODUCTION
Primary pancreatic lymphoma (PPL) is defined as an extra-
nodal lymphoma arising in the pancreas with the bulk of the
tumor localized to the pancreas (1). PPL is a very rare disease,
accounting for less than 0.5% of pancreatic tumors (1). Since
PPLs are reported to have a better prognosis compared to car-
cinomas, and chemotherapy is the mainstay of the treatment,
it is crucial to differentiate PPL from pancreatic carcinoma (2).
Most reports on PPL are single case reports. The objectives
of this study were to investigate the characteristics of PPL in
Korean patients, and to report our experience with this rare
disease.
MATERIALS AND METHODS
We retrospectively evaluated four patients who were patho-
logically diagnosed with PPL from January 1, 1997 to De-
cember 31, 2007 at Seoul National University Hospital. The
diagnosis of PPL was based on the criteria defined by Daw-
son et al. (3) (Table 1). The endpoints of this study were death
of the patient or June 30, 2008. Gender, age at diagnosis, clas-
sification of the lymphoma, cell lineage, presenting symp-
toms and signs, laboratory results, location of the tumor in
the pancreas, characteristics of computed tomography (CT)
imaging, involvement of lymph nodes, extrapancreatic organ
involvement, stage, treatment, and outcome of the patients
were evaluated. The follow-up and survival information were
obtained by contacting the Resident Service Division of the
Ministry of Public Administration and Security, Seoul, Korea,
and by reviewing medical records. All analyses were done
using SPSS for Windows Ver. 11.0 (SPSS Inc., Chicago, IL,
USA). This study was approved by the institutional review
board at our hospital (IRB number 1001-011-305).
RESULTS
Diagnosis, clinical presentation, and laboratory findings
A total of 4 patients were collected (Table 2). Three patients
were male. The diagnoses were: diffuse large B cell lymphoma
(n=2), Ki-1 (+) anaplastic large cell lymphoma (n=1), and
Burkitt lymphoma (n=1). Three cases were of B cell lineage
(diffuse large B cell lymphoma and Burkitt lymphoma); one
case was of T cell lineage (Ki-1 [+] anaplastic large cell lym-
phoma) (Fig. 1). The median age at diagnosis was 46.5 yr
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Primary Pancreatic Lymphoma in Korea-A Single Center Experience
The aim of this study was to report a single center experience of primary pancreat-
ic lymphoma (PPL) in Korea. We analyzed the clinicopathological data from four
PPL patients (three male, median age 36 yr) diagnosed from 1997 to 2007 at Seoul
National University Hospital. The diagnoses were: diffuse large B cell lymphoma
(n=2), Ki-1 (+) anaplastic large cell lymphoma (n=1), and Burkitt lymphoma (n=1).
Presenting symptoms and signs were: abdominal pain (n=4), pancreatitis (n=2),
weight loss (n=2) and abdominal mass (n=1). No patient underwent surgery. The
Ann Arbor stages of the patients were: IEA (n=1), IIEA (n=1), and IVEB (n=2). Two
patients underwent treatment. The stage IEA patient underwent chemotherapy and
radiation therapy that resulted in a complete remission. The stage IVEB patient who
underwent chemotherapy relapsed. This patient underwent subsequent peripheral
blood stem cell transplantation and is alive at 30 months. Two patients (stages IVEB
and IIEA) without treatment died at 0.8 and 7.0 months, respectively. For PPL pati-
ents, chemotherapy-based treatment, and addition of radiation therapy, if possible,
may offer good prognosis.
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(range 11-80 yr). All patients presented with abdominal pain;
two patients had evidence of pancreatitis. Other symptoms
and signs were weight loss (n=2) and a palpable abdominal
mass (n=1). No patient presented with fever or night sweats.
No patient had evidence of HIV infection; no patient had a
history of organ transplantation.
The serum lactate dehydrogenase (LDH) was measured in
three patients. One patient had an elevated serum LDH (>225
IU/L). The serum CEA and CA 19-9 were measured in two
patients. No patient had an elevated serum CEA or CA 19-
9. No patient had an elevated serum bilirubin. All patients
underwent ultrasound-guided percutaneous biopsy of the pan-
creas for tissue acquisition. There were no complications after
the biopsy. No patient underwent surgical procedures, either
for diagnostic or therapeutic purposes. Two of four patients
underwent bone marrow examination; no patient had bone
marrow involvement.
1. Neither superficial lymphadenopathy nor enlargement of mediasti-
nal lymph nodes on chest radiography
2. A normal leukocyte count in peripheral blood
3. Main mass in the pancreas with lymph-nodal involvement confined
to the peripancreatic region
4. No hepatic or splenic involvement
Table 1. Diagnostic criteria for PPL defined by Dawson et al. (3)
PPL, primary pancreatic lymphoma; M, male; F, female; DLBL, diffuse large B cell lymphoma; ALCL, Ki-1 (+) anaplastic large cell lymphoma; BM, bone
marrow.
Case
Presenting symptoms
and signs
Serum LDH
(100-225 IU/L)
Sex
Age
(yr)
Diagnosis
Serum CEA
(0-5 ng/mL)
Serum CA 19-9
(0-37 U/mL)
BM 
involvement
1 M 30 DLBL Pancreatitis 173 1.0 20 None
2 F 80 DLBL Abdominal pain, palpable  Not done Not done Not done Not done
mass, weight loss
3 M 63 ALCL Abdominal pain 179 1.7 8 Not done
4 M 11 Burkitt lymphoma Pancreatitis, weight loss 500 Not done Not done None
Table 2. Diagnosis, clinical presentation, and laboratory findings of PPL patients
Fig. 1. Pathology findings of case 4. (A) Photomicrograph shows
starry sky appearance and small non-cleaved cells (H&E, ×400).
(B) The specimen shows immunoreactivity for Ki-67 and (C) bcl-6.
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Radiological findings and stages
The CT findings are summarized in Table 3. The locations
of the lesions were body and tail (n=2), body (n=1), and dif-
fuse involvement of the entire pancreas (n=1). Three patients
demonstrated homogenous hypodense pancreatic lesions, and
one patient demonstrated a heterogenous hypodense pancre-
atic lesion. The median long diameter of the mass on CT was
5 cm (range 3-12 cm). Two patients who presented with pan-
creatitis showed minimal pancreatic duct dilatation on CT,
whereas one of the two patients who did not present with pan-
creatitis showed minimal main pancreatic duct dilatation and
the other showed no main pancreatic duct dilatation. One
patient showed lymph node enlargement on the same side
of the diaphragm. No patient demonstrated lymph node en-
largement above the diaphragm. One patient demonstrated
extrapancreatic organ involvement in both kidneys (Fig. 2).
The Ann Arbor stages of the patients were: IEA (n=1), IIEA
(n=1), and IVEB (n=2).
Treatment and prognosis
The patient with stage IEA disease underwent chemother-
apy and radiation therapy; this patient had a complete remis-
sion after treatment. The patient with stage IVEB disease had
chemotherapy; this patient showed relapse in the bone mar-
row, central nervous system, liver, and the kidneys 6.8 months
after the diagnosis. The patient underwent peripheral blood
stem cell transplantation and is alive at 30 months. Two pati-
ents (stages IVEB and IIEA) refused to be treated and did
not have any treatment, and both died 0.8 and 7.0 months
Fig. 2. CT findings of case 4. Homogenous, hypodense tumorous lesion is replacing almost the entire pancreas. (A) Dilatation of the main
pancreatic duct is noted. Multiple nodules are also found in both kidneys. (B) CT taken 1 yr after peripheral blood stem cell transplanta-
tion shows disappearance of lesions in the pancreas and kidneys.
A B
Case
LN 
involvement
below the
diaphragm
Long diameter 
of the mass 
(cm)
CT enhancement pattern Location
LN 
involvement
above the
diaphragm
Other organ
involvement
Stage
1 Body Homogenous, hypodense 3 No No None IEA
2 Body, tail (diffuse) Heterogenous, hypodense 7 No No None IVEB
3 Body, tail Homogenous, hypodense 3 Yes No None IIEA
4 Entire Homogenous, hypodense 12 No No Kidneys IVEB
Table 3. CT findings and stages of PPL patients
CT, computed tomography; PPL, primary pancreatic lymphoma; LN, lymph node.
Case Treatment Course Status
Follow-up
(months)
1 CHOP+RT Complete remission 45 No evidence 
of disease
2 None Dead 0.8 Dead
3 None Dead 7.0 Dead
4 COPADM Relapsed in BM,  30 No evidence
CNS, liver and kidneys of disease
at 6.8 months.
Underwent auto-PBSCT
Table 4. Treatment and prognosis of PPL patients
PPL, primary pancreatic lymphoma; CHOP, cyclophosphamide, dox-
orubicin, vincristine, and prednisone; RT, radiation therapy; COPADM,
cyclophosphamide, vincristine, prednisone, adriamycin, high-dose metho-
trexate; BM, bone marrow; CNS, central nervous system; PBSCT, periph-
eral blood stem cell transplantation.Primary Pancreatic Lymphoma 539
after diagnosis, respectively (Table 4).
DISCUSSION
PPL is a rare disease. In a review by Saif in 2006, fewer than
150 cases of PPL have been reported in English literature at
that time (4). Most are single case reports. Single center expe-
riences usually have included less than 15 cases (2, 5-11). A
nationwide study from Japan reported on 19 cases of PPL (12).
In our study, four patients were diagnosed over an 11-yr peri-
od. To the best of our knowledge, five cases of primary pan-
creatic lymphoma have been reported in Korea (13-17).
The clinical presentation of PPL is usually nonspecific. B
symptoms (weight loss, fever, and night sweats) are uncom-
mon. Therefore, the clinical presentation will usually help
little in distinguishing PPL patients from those with other
types of pancreatic tumors (18). Patient with a large, palpa-
ble pancreatic mass, presenting with abdominal pain with-
out jaundice, mass homogenous on imaging, with elevated
serum LDH may be suspected to have PPL (5, 19). The most
common presenting symptom of PPL is abdominal pain, fol-
lowed by abdominal mass, weight loss, jaundice, acute pan-
creatitis, small bowel obstruction, and diarrhea (4). In our
experience, all patients presented with abdominal pain, and
two patients had pancreatitis. No patient developed jaundice
in our study. B symptoms other than weight loss (i.e., fever
and night sweats) have been reported to be rare in PPL pati-
ents. Although weight loss was present in two patients, fever
and night sweats were not present in any of our patients.
The head of the pancreas is reported to be the most com-
mon location of PPL (2, 7, 12). However, the body/tail region
is reported to be more frequently affected in some reports (5).
In our study, one of four patients had pancreatic head involve-
ment; this patient showed diffuse involvement of the entire
pancreas.
There are reports of PPL arising in the setting of immun-
odeficiency, such as AIDS or organ transplant (20, 21). In our
study, however, no patient had evidence of AIDS or history
of organ transplantation.
The majority of PPLs are of the B-cell type (2, 5-7). T-
cell PPLs are rare, as described in Japanese series (12). In the
Japanese report, although not statistically significant, the 1-
yr survival for B-cell PPL (51.9%) was higher than that for
T-cell PPL (0%) (12). Among the four patients in our study,
only one patient had a T-cell lineage. This patient (initial stage
IIEA) did not undergo any treatment, and died seven months
after the diagnosis. 
There have been controversies over the treatment of PPLs.
However, chemotherapy, not surgery, is accepted as the main-
stay of the treatment (4, 18). Using complex treatment app-
roaches, cure rates of over 30% of PPL patients by chemo-
therapy was reported as early as the 1980s (22). With advances
in chemotherapy such as monoclonal antibodies, complete
remission can be expected in up to 85% of patients with dif-
fuse large B cell lymphoma (23). It is advocated that surgery
should be reserved for cases where percutaneous or endoscop-
ic biopsies are not diagnostic, or treatment with chemother-
apy and/or radiation therapy is not successful (4, 18). In our
study, no patient underwent surgical procedures. The stage
IEA patient, who underwent chemotherapy and radiation
therapy, achieved a long-term complete remission. The other
treated patient, who had stage IVEB disease, relapsed after
initial treatment. After subsequent treatment, this patient
is alive at 30 months. The treated patients are alive without
evidence of disease for more than two years.
In conclusion, PPL is a rare disease. Since chemotherapy
is the mainstay of the treatment, differentiation from other
pancreatic malignancies is crucial. Nonsurgical biopsy modal-
ities appear adequate for the diagnosis of PPL. Chemothera-
py-based treatment, and addition of radiation therapy, if pos-
sible, may provide a good prognosis.
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